We recently published our article Top 5 Healthcare Stocks According to Goldman Sachs. To read the full article, head on to Top 10 Healthcare Stocks According to Goldman Sachs. In this piece, we take a closer look at Eli Lilly and Company (NYSE:LLY), one of the names on that list, to explore its fundamentals, recent developments, and why it continues to attract investor interest.
A Quiet Rotation: Why Healthcare Stocks Are Suddenly Back in Focus
For much of the past decade, healthcare stocks have played the role of the market’s dependable but often overlooked performer—steady, defensive, and rarely the headline-grabber in an era dominated by artificial intelligence stocks, high-growth tech companies, and disruptive digital platforms. Yet history has a way of rewarding patience, and in 2026, the healthcare sector is once again reminding investors why it has long been considered one of the most resilient pillars of the global economy.
In a development that seasoned market observers would describe as both cyclical and inevitable, the S&P 500 Healthcare sector has quietly staged a meaningful comeback, advancing nearly 10% over the past six months as of mid-March—dramatically outperforming the broader index, which has barely moved. For veteran strategists who have witnessed multiple market cycles—from the dot-com bubble to the global financial crisis and the pandemic-era rally—this divergence is more than just a short-term anomaly. It is a signal of capital rotation, a classic shift in investor sentiment where funds begin flowing out of overextended sectors and into undervalued, asset-backed industries.
The Return of Defensive Growth in a Volatile Market
What makes the current environment particularly compelling is the convergence of macroeconomic uncertainty and structural demand. Healthcare has historically thrived during periods of geopolitical tension, inflationary pressure, and economic slowdown—not because it is immune to disruption, but because demand for healthcare services, medical devices, pharmaceuticals, and health-related products remains largely inelastic. People do not postpone critical treatments due to market cycles, and governments do not reduce healthcare spending without consequence.
This structural resilience is now intersecting with a powerful long-term growth narrative. According to industry projections frequently cited in global healthcare analysis and investment research, total global healthcare spending is expected to expand from approximately $11.2 trillion today to an astonishing $20.5 trillion by 2050. For investors searching for long-term growth stocks, this trajectory places healthcare among the most compelling sectors in terms of both scale and durability.
Yet beneath these bullish projections lies a more complex reality—one that introduces both risk and opportunity. The World Economic Forum, in its January 2026 outlook, highlighted a looming healthcare workforce shortage that could reach 10 million workers by 2030, alongside ageing populations and cost structures rising faster than GDP. These pressures are not theoretical; they are already reshaping how healthcare systems operate, invest, and innovate.
The AI Paradox in Healthcare Innovation
Ironically, while artificial intelligence has driven massive valuation expansion in sectors like semiconductors, cloud computing, and enterprise software, its impact on healthcare has been far more uneven. Despite more than $100 billion poured into U.S. digital health investments since 2010—a figure that underscores the sector’s strategic importance—most AI in healthcare solutions remain fragmented, difficult to scale, and constrained by regulatory complexity.
Over 70% of FDA-approved AI applications are concentrated in medical imaging, a niche that, while valuable, represents only a fraction of the broader healthcare ecosystem. Electronic health records remain siloed, interoperability challenges persist, and strict compliance frameworks slow down widespread deployment. For investors tracking digital health trends, this creates what many analysts describe as an “AI paradox”—a sector with immense technological potential but limited near-term scalability.
This is precisely where opportunity begins to emerge. Industry experts increasingly point to clinical entrepreneurship and integrated healthcare platforms as the next frontier, emphasizing that unlocking the full value of healthcare innovation will require coordinated action among stakeholders—ranging from hospitals and regulators to private capital and technology providers. In the language of modern investment strategy, healthcare is transitioning from a purely defensive sector into a hybrid model combining defensive stability with innovation-driven upside.
The Great Rotation: From Asset-Light to Asset-Heavy Investments
Perhaps the most important shift underpinning the renewed interest in healthcare stocks is the broader market rotation now taking shape. After years of dominance by asset-light business models—particularly in software and platform-based companies—investors are beginning to reprice the value of tangible, capital-intensive assets.
Goldman Sachs strategists have been particularly vocal about this transition, noting that markets are increasingly rewarding companies with physical infrastructure, complex engineering systems, and high barriers to entry. These include healthcare providers, medical equipment manufacturers, pharmaceutical companies, and life sciences firms—businesses built not just on code, but on networks, capacity, and specialized expertise that are difficult to replicate.
As Guillaume Jaisson of Goldman Sachs observed, investors are placing a premium on “capacity, networks, infrastructure and engineering complexity,” signaling a fundamental shift in how value is being assessed in today’s market environment. For those analyzing healthcare sector performance, this insight is critical. Hospitals, diagnostic networks, manufacturing facilities, and distribution systems are no longer viewed as cost burdens—they are strategic assets.
Morgan Stanley strategists have echoed this sentiment, pointing out that as high-growth tech stocks begin to normalize from historically elevated valuations, capital is gradually rotating into sectors trading at discounts. Healthcare, which has underperformed relative to the broader market in recent years, now stands out as one of the most attractive value opportunities.
Valuation Discounts and the Case for Re-Rating
From a valuation perspective, the argument becomes even more compelling. Goldman Sachs strategist David Kostin previously highlighted that the healthcare sector’s prolonged underperformance has pushed valuations to near-record discounts relative to the broader market. At a time when many technology stocks continue to trade above historical norms, healthcare equities offer a rare combination of discounted pricing, stable cash flows, and long-term growth visibility.
For experienced investors, this setup is familiar. Market leadership does not remain static. Periods of underperformance often lay the groundwork for future outperformance, particularly when supported by strong fundamentals. In the case of healthcare, those fundamentals include demographic tailwinds, rising global demand, and an evolving innovation landscape that is still in its early stages.
Why This Moment Matters for Investors
What distinguishes the current inflection point from previous cycles is the alignment of multiple forces: macroeconomic uncertainty driving demand for defensive stocks, structural growth fueled by global healthcare spending, technological disruption that remains underutilized, and a clear shift in market preference toward asset-heavy companies.
Taken together, these dynamics suggest that the healthcare sector is no longer simply a safe haven—it is becoming a strategic allocation. For investors searching for the best healthcare stocks, undervalued healthcare companies, or long-term investment opportunities in healthcare, the present moment offers a rare window where risk and reward appear unusually well-balanced.
As capital continues to rotate and valuations adjust, the next phase of market leadership may not be led solely by the fastest-growing companies, but by those with the strongest foundations. In that context, examining Goldman Sachs’ top healthcare stock picks is not just timely—it may prove essential for investors aiming to position themselves ahead of the next major shift in the financial markets.
CHECK THIS OUT: Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next and Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026.
Our Methodology
To identify the top 10 healthcare stocks according to Goldman Sachs, our team reviewed Goldman Sachs’ latest portfolio disclosures and strategic research, narrowing the focus to its highest-conviction healthcare names. The selection prioritizes companies with recent catalysts, strong analyst backing, and increasing interest from institutional investors and leading hedge funds, ensuring a balance of momentum, fundamentals, and market relevance.
Top 5 Healthcare Stocks According to Goldman Sachs
1. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY), trading at $922.39, stands at the forefront of one of the most transformative trends in modern healthcare—the rapid rise of obesity and metabolic disease treatments. With a Goldman Sachs equity stake of $6.38 billion, the company has emerged as the top healthcare stock on this list, reflecting both its market leadership and future growth potential.
The latest reaffirmation of an Outperform rating by Bernstein, coupled with a $1,300 price target, highlights the strong conviction among analysts regarding Eli Lilly’s trajectory. Central to this optimism is the company’s aggressive expansion in GLP-1 therapies, particularly through its blockbuster drugs Mounjaro and other obesity-focused treatments.
The launch of the Employer Connect platform marks a strategic innovation that extends beyond traditional drug development. By partnering with program administrators such as GoodRx and Cost Plus Drugs, Eli Lilly is addressing one of the biggest barriers in healthcare—access and affordability. The platform allows employers to customize coverage for GLP-1 medications, effectively broadening patient access while managing costs.
Prescription data further reinforces the strength of demand, with Mounjaro recording over 724,500 prescriptions and more than 361,000 new prescriptions in a single week. For investors analyzing healthcare stocks and obesity drug leaders, these figures are not just impressive—they signal a structural shift in how chronic diseases are treated and managed.
Eli Lilly’s dominance in this space places it at the center of multiple high-growth markets, including diabetes, obesity, oncology, and immunology. As one of the most searched healthcare stocks and biotech leaders, the company represents a convergence of innovation, scale, and market opportunity.
For long-term investors, Eli Lilly is not merely participating in the evolution of healthcare—it is actively shaping its future.
READ ALSO: Top 10 Small-Cap FDA Catalyst Biotech Stocks and Top 5 Best Biotech Stocks of February 2026.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
